Literature DB >> 11514691

Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study.

M Pelkonen1, I L Notkola, H Tukiainen, M Tervahauta, J Tuomilehto, A Nissinen.   

Abstract

BACKGROUND: Permanent smoking cessation reduces loss of pulmonary function. Less is known in the long term about individuals who give up smoking temporarily or quitters with lower initial pulmonary function. Little is known also about the relationship between decline in pulmonary function and mortality. We examined these aspects and the association between smoking, decline in pulmonary function, and mortality.
METHODS: Two middle aged male Finnish cohorts of the Seven Countries Study and their re-examinations on five occasions during a 30 year period of follow up were analysed.
RESULTS: During the first 15 years (n=1007) adjusted decline in forced expiratory volume in 0.75 seconds (FEV(0.75)) was 46.4 ml/year in never smokers, 49.3 ml/year in past smokers, 55.5 ml/year in permanent quitters, 55.5 ml/year in intermittent quitters, and 66.0 ml/year in continuous smokers (p<0.001 for trend). Quitters across the entire range of baseline FEV(0.75) had a slower decline in FEV(0.75) than continuous smokers. Among both continuing smokers and never smokers, non-survivors had a significantly (p<0.001) more rapid decline in FEV(0.75) than survivors. The adjusted relative hazard for total mortality was 1.73 (95% confidence interval (CI) 1.41 to 2.11) and 1.24 (95% CI 1.02 to 1.52) in the lowest and middle tertiles of decline in FEV(0.75). Never smokers, past smokers, and quitters had significantly lower total mortality than continuous smokers, partly because of their slower decline in FEV(0.75).
CONCLUSION: These results highlight the positive effect of smoking cessation, even intermittent cessation, on decline in pulmonary function. Accelerated decline in pulmonary function was found to be a risk factor for total mortality. The beneficial effect of smoking cessation on mortality may partly be mediated through a reduced decline in pulmonary function.

Entities:  

Mesh:

Year:  2001        PMID: 11514691      PMCID: PMC1746131          DOI: 10.1136/thorax.56.9.703

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Dietary factors and pulmonary function: a cross sectional study in middle aged men from three European countries.

Authors:  C Tabak; H A Smit; L Räsänen; F Fidanza; A Menotti; A Nissinen; E J Feskens; D Heederik; D Kromhout
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

2.  Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults.

Authors:  J H Ware; D W Dockery; T A Louis; X P Xu; B G Ferris; F E Speizer
Journal:  Am J Epidemiol       Date:  1990-10       Impact factor: 4.897

3.  The natural history of chronic airflow obstruction.

Authors:  C Fletcher; R Peto
Journal:  Br Med J       Date:  1977-06-25

4.  The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms.

Authors:  I B Tager; M R Segal; F E Speizer; S T Weiss
Journal:  Am Rev Respir Dis       Date:  1988-10

5.  Selection effects of repeatability criteria applied to lung spirometry.

Authors:  E A Eisen; J M Robins; I A Greaves; D H Wegman
Journal:  Am J Epidemiol       Date:  1984-11       Impact factor: 4.897

6.  Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men.

Authors:  M Pelkonen; H Tukiainen; M Tervahauta; I L Notkola; S L Kivelä; Y Salorinne; A Nissinen
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

7.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

Authors:  P D Scanlon; J E Connett; L A Waller; M D Altose; W C Bailey; A S Buist; D P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

8.  Effects of smoking and changes in smoking habits on the decline of FEV1.

Authors:  P Lange; S Groth; G J Nyboe; J Mortensen; M Appleyard; G Jensen; P Schnohr
Journal:  Eur Respir J       Date:  1989-10       Impact factor: 16.671

9.  Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation.

Authors:  A E Camilli; B Burrows; R J Knudson; S K Lyle; M D Lebowitz
Journal:  Am Rev Respir Dis       Date:  1987-04

10.  Longitudinal lung function decline in subjects with respiratory symptoms.

Authors:  C B Sherman; X Xu; F E Speizer; B G Ferris; S T Weiss; D W Dockery
Journal:  Am Rev Respir Dis       Date:  1992-10
View more
  29 in total

1.  A novel technique to explore the functions of bronchial mucosal T cells in chronic obstructive pulmonary disease: application to cytotoxicity and cytokine immunoreactivity.

Authors:  M W Lethbridge; D M Kemeny; J C Ratoff; B J O'Connor; C M Hawrylowicz; C J Corrigan
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

2.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors:  Michael Spencer; Andrew H Briggs; Ronald F Grossman; Laureen Rance
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Impact of Smoking on the Atrial Substrate Characteristics in Patients with Atrial Fibrillation.

Authors:  Ta-Chuan Tuan; Shih-Lin Chang; Shih-Ann Chen
Journal:  J Atr Fibrillation       Date:  2008-09-16

4.  Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study.

Authors:  N S Godtfredsen; J Vestbo; M Osler; E Prescott
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

5.  Combined effect of lung function level and decline increases morbidity and mortality risks.

Authors:  Penelope Baughman; Jacob L Marott; Peter Lange; Christopher J Martin; Anoop Shankar; Edward L Petsonk; Eva Hnizdo
Journal:  Eur J Epidemiol       Date:  2012-12-14       Impact factor: 8.082

Review 6.  Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.

Authors:  Edwin J Wagena; Maurice P A Zeegers; Constant P van Schayck; Emiel F M Wouters
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project.

Authors:  Richard Hooper; Peter Burney; William M Vollmer; Mary Ann McBurnie; Thorarinn Gislason; Wan C Tan; Anamika Jithoo; Ali Kocabas; Tobias Welte; A Sonia Buist
Journal:  Eur Respir J       Date:  2011-12-19       Impact factor: 16.671

8.  Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy.

Authors:  David M MacDonald; Anne C Melzer; Gary Collins; Anchalee Avihingsanon; Kristina Crothers; Nicholas E Ingraham; Henry Mugerwa; Matti Ristola; Jonathan Shuter; Ken M Kunisaki
Journal:  J Acquir Immune Defic Syndr       Date:  2018-11-01       Impact factor: 3.731

Review 9.  Smoking cessation: significance and implications for children.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

10.  Associations between baseline biomarkers and lung function in HIV-positive individuals.

Authors:  David M MacDonald; Alexander D Zanotto; Gary Collins; Jason V Baker; Marcin Czarnecki; Eliana Loiza; Daniel E Nixon; Vasileios Papastamopoulos; Chris H Wendt; Robin Wood; Ken M Kunisaki
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.